ARS Pharmaceuticals, Inc. (SPRY) Financials

SPRY Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 249.5 million 237.0 million
March 31, 2026 287.6 million 226.3 million
Dec. 31, 2025 327.7 million 213.4 million
Sept. 30, 2025 372.8 million 225.1 million

SPRY Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -60.9 million 12.4 million
March 31, 2026 -44.9 million 7.4 million
Dec. 31, 2025 -43.5 million 5.7 million
Sept. 30, 2025 -47.2 million 5.7 million

SPRY Net Income

No data available :(

SPRY Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 143.8 million 171.6 million -
March 31, 2026 201.0 million 96.5 million -
Dec. 31, 2025 245.0 million 96.4 million -
Sept. 30, 2025 288.2 million 949000 1.5 million

SPRY Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 99.3 million
March 31, 2026 99.3 million
Dec. 31, 2025 98.6 million
Sept. 30, 2025 98.8 million

SPRY Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 4.7 million 77.6 million -
March 31, 2026 - 4.3 million 72.2 million -
Dec. 31, 2025 - 3.4 million 60.0 million -
Sept. 30, 2025 197000 2.8 million 74.8 million -

SPRY Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 33.7 million 12.8 million
March 31, 2026 22.7 million 6.3 million
Dec. 31, 2025 28.1 million 3.2 million
Sept. 30, 2025 32.5 million 8.2 million

SPRY Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SPRY

Price: $5.50

52 week price:
4.91
18.00

Earnings Per Share: -2.18 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 634.5 million

Links: